Our Studies
Changing Medicine To Change Lives
Ongoing Studies
Open to Enrollment
-
ACHIEVE-4 - Study will test how safe and well the investigational
medicine (the medicine being studied) works for blood glucose and weight management compared with insulin therapy in patients with type 2 diabetes and excess weight who are at risk for heart disease or stroke. -
REDEFINE 3 - Studies the combination of cagrilinitide and semaglutide (CagriSema), which has the potential to impact cardiovascular risk factors
-
ARCTIC - Studies baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease (CKD) progression in participants with CKD and high blood pressure.
-
ZENITH - Study to determine whether zibotentan and dapagliflozin compared to dapagliflozin alone to slow decline in kidney function.
If you are interested in participating in a research study
please contact us at:
Phone (Call): (562) 598-0600 ext. 205/206
Phone (Text): (562) 343-0909
Fax: (562) 430-5661
Completed Studies
-
A Study investigating the safety and efficacy of once weekly NNC0519-0130 in participants with type 2 diabetes mellitus.
-
ZEUS Study - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation.
-
SOUL Study - A Randomized, double-blind, parallel-group, placebo-controlled trial comparing oral semaglutide vs. placeboOD added to standard of care in patients with T2D at high risk of CV events.
-
PIONEER Study - Efficacy and safety of once-daily oral semaglutide 25mg and 50 mg compared with 14mg in subjects with type 2 diabetes.
-
COMBINE Study - A 52 week study comparing the efficacy and safety of once weekly IcoSema and once weekly insulin icodec, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with daily basal insulin.
-
GERAS Study - Longitudinal Cohort Study of Resource use and Cost of Mild Cognitive Impairment and Mild Dementia due to Alzheimer's Disease in the United States
-
AXSOME Study - A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety Of AXS-05-AD-301 For the Treatment of Agitation in Subject with Dementia of the Alzheimer’s Type
-
DEVOTE Study - A trial comparing Cardiovascular Safety of insulin degludec versus insulin glargine in subjects with type II diabetes and high-risk cardiovascular events
-
PIONEER 3 Study - Efficacy and long-term safety of oral semaglutide vs. sitagliptin in subjects with type 2 diabetes
-
PIONEER 4 Study - Efficacy and Safety of Oral Semaglutide vs. Liraglutide and vs. Placebo in subjects with type 2 Diabetes Mellitus
-
A Trial comparing the efficacy and safety of insulin degludec and insulin glargine 300 units/mL in subjects with type 2 diabetes mellitus inadequately treated with basal insulin with or without
oral anti-diabetic drugs (NN1250-4252) -
SEPRA Study - Long Term comparative effectiveness of once weekly semaglutide vs. standard of care in a real
world adult US population with T2D – a randomized pragmatic clinical trial. -
CAGRI-SEMA Study - Efficacy and safety of co-administration of cagrilintide s.c. 2.4 mg and semaglutide s.c. 2.4 mg once weekly in subjects with type 2 diabetes. (NN9838-4862)
-
A Phase III study, Randomized, Double-Blind, Placebo-Controlled
Study to evaluate the Efficacy and Safety of Tetracycline in patients with Rheumatoid Arthritis -
A Multicenter, Randomized, Double-Blind, Placebo-Controlled
Study to Evaluate the Efficacy and safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) -
An informational study on patients with type II diabetes and CKD of stage II or higher
-
CHAMP Study - Observational Registry of Treatment patterns in U.S. Heart Failure Patients with Reduced Ejection Fraction.
Think you're an eligible study participant?
Contact us!
(562) 598-0600 ext. 205